NEWS
LATEST
FULL LIST
-
restor3d Completes First Clinical Cases of Fully Personalized 3D-Printed Knee Replacement System
restor3d has announced a major clinical milestone: the first surgeries using the iTotal Identity™ CR 3DP Porous Fully Personalized Total Knee Replacement System, the first cementless knee implant system built entirely around patient-specific design and advanced 3D-printed porous structures. This marks a transformative moment in orthopedics—a shift from standardized implants to fully individualized joint replacements…
-
Revalia Bio Secures ~$30M Government Contract to Build the Future of Human-First Drug Development
Revalia Bio, a Yale-born startup redefining drug development through real human donor tissue, has secured a landmark ~$30 million U.S. government contract—one of the largest ever awarded to a seed-stage biotechnology company. The announcement marks a turning point not only for Revalia, but for the broader movement away from animal-model drug development and toward human-first…
-
Inside Curi Bio’s Human Tissue Platforms: How They Work, What the $10M Series B Will Accelerate, and Why It Matters
In a recent Series B financing round led by DreamCIS, Curi Bio announced it has raised $10 million to expand its human-relevant bioengineering platforms for drug discovery. What exactly has Curi built today? How do its technologies work? And where will this new capital be deployed? Below, we break down the mechanisms, applications, and strategic…
-
Xeltis Secures Nearly €50M to Advance aXess Toward Market Entry as New Data Strengthen Clinical Profile
Xeltis, a Dutch clinical-stage company developing fully bioresorbable cardiovascular implants, has secured nearly €50 million in new financing from the European Investment Bank (EIB) and existing shareholders. The financing arrives as new peer-reviewed 12-month clinical data provide the most detailed look yet at the performance of aXess, Xeltis’ regenerative hemodialysis access conduit. Together, the capital…
-
The Rise of the Tiger – Tiger BioSciences: Building a Fully Integrated Platform for Regenerative Medicine
Conshohocken, PA – Founded in 2023, Tiger BioSciences LLC has rapidly emerged as one of the most vertically integrated companies in the regenerative medicine and medical-technology landscape. Based just outside Philadelphia, the firm operates a network of divisions spanning donor tissue recovery, advanced processing, R&D, manufacturing, and global distribution—positioning itself as a full-spectrum provider of…
-
InSphero Acquires Doppl SA, Expanding Its 3D Cell Culture Portfolio with the Gri3D® Platform
InSphero AG, a global leader in 3D cell-based assay systems and organ-on-chip models, has acquired Doppl SA, a Swiss company known for its microstructured 3D cell-culture technology. The move solidifies InSphero’s position as a comprehensive provider of scalable, physiologically relevant in vitro solutions for drug discovery and translational research. Why This Acquisition Makes Sense Both…
-
Tiger Aesthetics Invests in GenesisTissue to Advance Regenerative Breast Reconstruction
Tiger Aesthetics Medical, a division of Tiger Biosciences, has announced a strategic investment in GenesisTissue Inc., a biotechnology company developing 3D bioprinted scaffolds for breast reconstruction and cosmetic surgery. The partnership aims to accelerate the development of regenerative tissue solutions intended to provide natural, long-term alternatives to traditional implants. Investment Overview The collaboration builds on…
-
Lattice Medical Raises €43M to Transform Post-Cancer Reconstruction and Scale 3D Bioprinting in France
In one of France’s largest medtech deals of the year, Lattice Medical has secured €43 million in Series B funding to accelerate the clinical and industrial development of its MATTISSE implant — a 3D-printed, fully resorbable scaffold designed for natural breast tissue regeneration after cancer. The round was led by the SPI Fund, managed by…
-
Why Vertex Is Staying the Course on VX-880 (Zimislecel) — Even as Novo Nordisk Pulls Back
The recent retreats by major pharmas such as Novo Nordisk, which exited cell therapy entirely, and the shutdown of encapsulated islet programs elsewhere, have sent shockwaves through the Type 1 diabetes cell therapy field. In contrast, Vertex appears to be doubling down—not walking away. That divergence in strategy reveals where the science, and the business…
-
Mytos Launches Automated CDMO to Scale Regenerative Cell Therapies
London, UK — Mytos has officially launched its automated CDMO (Contract Development and Manufacturing Organization), powered by the company’s proprietary iDEM™ automation platform, with a mission to tackle one of regenerative medicine’s enduring challenges: the scalable, cost-efficient manufacturing of stem cell–derived therapies. Operating within the CGT Catapult’s Stevenage Manufacturing Innovation Centre, Mytos’ new facility aims…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 